Here, we demonstrate that newly diagnosed pediatric DIPG patients with augmented TGFB2 mRNA levels in their primary tumor samples, but not pediatric DIPG patients with augmented transforming growth factor beta 1 (TGFB1) or transforming growth factor beta 3 (TGFB3) mRNA levels, have significantly worse progression-free survival (PFS) as well as overall survival (OS) than other pediatric DIPG patients. The gene discussed is TGFB2; the disease is diffuse intrinsic pontine glioma.